[Breaking] US Moderna "All Participants Show Antibody Response in COVID-19 Vaccine Clinical Trial"
[Asia Economy Reporter Heo Midam] Major foreign media reported on the 14th (local time) that the U.S. pharmaceutical company Moderna announced it succeeded in inducing antibody formation in all subjects during the initial clinical trial for the development of a novel coronavirus infection (COVID-19) vaccine.
According to the trial results published in the medical journal New England Journal of Medicine (NEJM), none of the participants experienced serious side effects.
However, more than half of the subjects who received a second dose or a large amount of the drug showed mild reactions such as fatigue, headache, chills, and muscle pain.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Moderna began the world's first clinical trial administering a COVID-19 vaccine drug to humans on March 16. Moderna is currently preparing for Phase 3, the final stage before drug approval.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
